Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01836523 · ClinicalTrials.gov registry record · Phase 3
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
A Phase 3 study of Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,398
- Enrollment target
- 20
- Study locations
NCT01836523 is a Phase 3 study of Diabetes and Diabetes Mellitus, Type 1 that has completed, run by Novo Nordisk A/S. The registered enrollment target is 1,398 participants, below the 3,024-participant average among 338 other Diabetes trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT01836523, a Phase 3 study of Diabetes and Diabetes Mellitus, Type 1, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,398 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is conducted globally. The aim of the trial is to confirm the efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes. The total trial duration per subject is approximately 58 weeks.
Conditions Studied
Interventions
- DRUG placebo
- DRUG liraglutide
Study Locations (20)
California
- Novo Nordisk Investigational Site - Concord
- Novo Nordisk Investigational Site - Encino
- Novo Nordisk Investigational Site - Escondido
- Novo Nordisk Investigational Site - Huntington Beach
- Novo Nordisk Investigational Site - La Mesa
- Novo Nordisk Investigational Site - Lancaster
- Novo Nordisk Investigational Site - Monterey
- Novo Nordisk Investigational Site - San Mateo
- Novo Nordisk Investigational Site - San Ramon
- Novo Nordisk Investigational Site - Walnut Creek
Florida
- Novo Nordisk Investigational Site - Fort Lauderdale
- Novo Nordisk Investigational Site - Hialeah
- Novo Nordisk Investigational Site - Jacksonville
- Novo Nordisk Investigational Site - Tampa
Georgia
- Novo Nordisk Investigational Site - Atlanta
- Novo Nordisk Investigational Site - Atlanta
- Novo Nordisk Investigational Site - Marietta
- Novo Nordisk Investigational Site - Roswell
Arkansas
- Novo Nordisk Investigational Site - Little Rock
Colorado
- Novo Nordisk Investigational Site - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,398 participants |
| Start Date | 2013-11 |
| Est. Completion | 2015-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01836523
The ClinicalTrials.gov registry entry for NCT01836523 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,398 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,024-participant average among 338 other Diabetes trials with a reported enrollment target (54% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01836523 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT01836523 about?
NCT01836523 is a clinical study titled "The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes". This trial is conducted globally. The aim of the trial is to confirm the efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes. The total trial duration per subject is approximately 58 weeks.
What is the current status of trial NCT01836523?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,398 participants. The study started on 2013-11. Estimated completion is 2015-06.
What conditions does trial NCT01836523 study?
This clinical trial studies the following conditions: Diabetes, Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT01836523?
The interventions under investigation include: placebo (DRUG), liraglutide (DRUG).
Who is sponsoring clinical trial NCT01836523?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01836523 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial to Assess Chelation Therapy in Critical Limb Ischemia
RECRUITING · Phase 3
-
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes
COMPLETED · Phase 3
-
Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes
COMPLETED · Phase 3
-
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
COMPLETED · Phase 3
-
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.